Navigation Links
Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
Date:9/12/2013

sease difficult to treat and is an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

About Pancreatic Cancer
In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the lowest of any cancer. In 2013, it is estimated that almost 45,000 new cases of pancreatic cancer will be diagnosed. About one-in-78 people in the U.S. will develop the disease, affecting equal numbers of men and women, almost always after the age of 45. Its tendency to spread prior to diagnosis makes it the fourth deadliest cancer with a less than six percent five-year relative survival rate, with more than 38,000 people succumbing to the disease each year.1-2

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement 
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements co
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
2. Halozyme Reports Second Quarter 2013 Financial Results
3. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
4. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
5. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
6. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
7. Halozyme Reports First Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
9. Halozyme Therapeutics Names Matt Posard to Board of Directors
10. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... NEW YORK , July 31, 2015  Seeger Weiss ... Drug Administration (FDA) issued a warning letter to C.R. Bard, ... for not taking adequate strides to correct violations the agency ... aware of these violations after the FDA cited them during ... 05, 2015, in Bard,s Tempe, AZ , ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... , ... PTC Therapeutics, Inc. (PTC) today announced the initiation of an ... men with nonsense mutation Duchenne/ Becker muscular dystrophy (nmDBMD) ... trial is evaluating the best methods for measuring functional abilities ...
... , , OXFORD, England , ... focused on allergy, today announced that it has,initiated phase II ... cat allergies. With the start of these studies, and the ... company,now has three clinical development programmes in phase II. Each ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 2Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it ... Bronx campus. The goal is to bring this Torah – dating from 1880 – ... rituals and religious services. , Scroll No. 515, from the town of Taus-Domazlice, ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... supporters will discuss implications of federal health-reform bills at the ... at 9:00 am. Health-policy experts will examine which proposed legislation ... will make sure Americans are not forced to have a ... cradle to grave and that citizens are not forced to ...
... Pa., June 17 The GBS/CIDP Foundation International, ... afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating ... Patricia A. Bryant to the position of Executive ... succeeds Estelle L. Benson, who along with her ...
... (June 17, 2009) Two new studies published by ... demonstrate a need for more vigilant monitoring for seizure ... subtle seizures that are typically unrecognized. These subtle seizures ... damage, death and severe disability. Published in recent ...
... A $4.15 million, four-year National Institutes of Health grant ... Medicine to conduct the first health study of teenage ... Dennis Fortenberry, M.D., M.S., professor of pediatrics in the ... follow 72 males, ages 14-17 years, for three years. ...
... , CiNet Acquires Industry-Leading Training Assets to Help ... Workplace Efficiency , , DALLAS, June 17 ... emerging eLearning company serving customers across the public ... the formal launch of its business operations. ...
... also guards against infection, study shows , WEDNESDAY, June ... development of emphysema also defends the lungs against bacterial ... thought that the only thing macrophage elastase, matrix metalloproteinase-12 ... the tissue destruction seen in emphysema patients. , "But ...
Cached Medicine News:Health News:GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 3Health News:Cellular telephones to expand knowledge of health behaviors and microorganisms in adolescent males 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 3Health News:Lung Enzyme Both Friend and Foe 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: